Autologous Transplantation of Adult Salivary Gland Stem Cells for Submandibular Gland Function Restoration Post-Radiotherapy in Head and Neck Cancer Patients

The primary objective of the study is to evaluate the efficacy of **autologous transplantation** of adult salivary gland stem cells in restoring submandibular gland function in patients who have undergone radiotherapy for head and neck cancer. This is clinically relevant as radiotherapy can lead to significant salivary gland dysfunction, impacting the quality of life due to symptoms such as dry mouth and difficulty swallowing. The study targets patients who have been operated on with curative intent for head and neck cancer and have an indication for bilateral postoperative radiotherapy, with or without chemotherapy.

The clinical trial involves **patients** who have undergone surgery with curative intent for **head and neck cancer** and have an indication for bilateral postoperative radiotherapy, with or without chemotherapy. The study population includes both male and female participants, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The trial aims to gather data on this particular patient group, although the main objective of the study has not been detailed by the sponsor.

The clinical trial is designed to evaluate the efficacy of autologous transplantation of adult salivary gland stem cells in restoring submandibular gland function in patients who have undergone surgery for head and neck cancer and are indicated for bilateral postoperative radiotherapy, with or without chemotherapy. This trial is a **Phase 1** study, which typically focuses on assessing the safety and feasibility of the intervention. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date was May 10, 2022, and the trial is expected to conclude by January 1, 2030.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into either the treatment or control group. The study will include multiple follow-up visits to monitor the participants' health status and the intervention's effects. These visits are crucial for collecting data on primary and secondary endpoints, although specific endpoints are not detailed in the available data. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the long-term outcomes of the intervention.

The expected length of participant involvement will vary depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any protocol deviations that compromise the integrity of the trial. Participants' safety and well-being are prioritized throughout the study, with regular monitoring to ensure any potential risks are promptly addressed. The trial's design and procedures are aligned with ethical standards and regulatory requirements to ensure the highest quality of clinical research.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is May 10, 2022, with an anticipated end date of January 1, 2030. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the drug's effects, which may include **biomarker** levels or other relevant clinical measures. The trial will likely employ validated scales and laboratory tests to gather data at predetermined intervals throughout the study period. The analysis of these efficacy parameters will be conducted using standard statistical methods appropriate for early-phase clinical trials. The results will contribute to understanding the investigational product's potential therapeutic benefits and inform subsequent trial phases.